Do analysts prefer ENSC or APLT?

Applied Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than Ensysce Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Do analysts recommend TPST or ENSC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ENSC or NAII?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer ENSC or PASG?

Passage Bio has a consensus price target of $13.25, indicating a potential upside of 185.01%. Given Passage Bio's stronger consensus rating and higher probable upside, analysts clearly believe Passage Bio is more favorable than Ensysce Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11

Do analysts prefer ENSC or GTBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Ensysce Biosciences (ENSC) Competitors

$0.38 -0.01 (-2.13%)

As of 03:36 PM Eastern

Compare

ENSC vs. APLT, TPST, NAII, PASG, and GTBP

Should you buy Ensysce Biosciences stock or one of its competitors? MarketBeat compares Ensysce Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ensysce Biosciences include Applied Therapeutics (APLT), Tempest Therapeutics (TPST), Natural Alternatives International (NAII), Passage Bio (PASG), and GT Biopharma (GTBP).

How does Ensysce Biosciences compare to Applied Therapeutics?

Ensysce Biosciences (NASDAQ:ENSC) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Ensysce Biosciences' average media sentiment score of 0.00 equaled Applied Therapeutics'average media sentiment score.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
Applied Therapeutics	Neutral

Applied Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than Ensysce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Ensysce Biosciences has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

Ensysce Biosciences has higher revenue and earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	1.14	-$10.18M	-$3.35	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

Applied Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. Applied Therapeutics' return on equity of -340.84% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
Applied Therapeutics	N/A	-340.84%	-175.00%

Summary

Applied Therapeutics beats Ensysce Biosciences on 9 of the 13 factors compared between the two stocks.

How does Ensysce Biosciences compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Ensysce Biosciences has higher revenue and earnings than Tempest Therapeutics. Tempest Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
Ensysce Biosciences	$5.07M	1.14	-$10.18M	-$3.35	N/A

In the previous week, Tempest Therapeutics' average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score.

Company	Overall Sentiment
Tempest Therapeutics	Neutral
Ensysce Biosciences	Neutral

Tempest Therapeutics has a beta of -1.72, meaning that its share price is 272% less volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 36.2% of Tempest Therapeutics shares are held by insiders. Comparatively, 2.8% of Ensysce Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tempest Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. Tempest Therapeutics' return on equity of -355.61% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
Ensysce Biosciences	-250.39%	-766.45%	-256.59%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Tempest Therapeutics beats Ensysce Biosciences on 6 of the 11 factors compared between the two stocks.

How does Ensysce Biosciences compare to Natural Alternatives International?

Ensysce Biosciences (NASDAQ:ENSC) and Natural Alternatives International (NASDAQ:NAII) are related small-cap companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Natural Alternatives International has a net margin of -10.13% compared to Ensysce Biosciences' net margin of -250.39%. Natural Alternatives International's return on equity of -12.21% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
Natural Alternatives International	-10.13%	-12.21%	-5.30%

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by insiders. Comparatively, 20.8% of Natural Alternatives International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Ensysce Biosciences has higher earnings, but lower revenue than Natural Alternatives International. Natural Alternatives International is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	1.14	-$10.18M	-$3.35	N/A
Natural Alternatives International	$129.86M	0.11	-$13.57M	-$2.39	N/A

Ensysce Biosciences has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Natural Alternatives International has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

In the previous week, Ensysce Biosciences' average media sentiment score of 0.00 equaled Natural Alternatives International'saverage media sentiment score.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
Natural Alternatives International	Neutral

Summary

Natural Alternatives International beats Ensysce Biosciences on 7 of the 11 factors compared between the two stocks.

How does Ensysce Biosciences compare to Passage Bio?

Ensysce Biosciences (NASDAQ:ENSC) and Passage Bio (NASDAQ:PASG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Ensysce Biosciences has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Passage Bio has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

Passage Bio has a consensus price target of $13.25, indicating a potential upside of 185.01%. Given Passage Bio's stronger consensus rating and higher probable upside, analysts clearly believe Passage Bio is more favorable than Ensysce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

In the previous week, Passage Bio had 2 more articles in the media than Ensysce Biosciences. MarketBeat recorded 2 mentions for Passage Bio and 0 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
Passage Bio	Neutral

Ensysce Biosciences has higher revenue and earnings than Passage Bio. Passage Bio is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	1.14	-$10.18M	-$3.35	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

Passage Bio has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. Passage Bio's return on equity of -150.88% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
Passage Bio	N/A	-150.88%	-59.78%

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by company insiders. Comparatively, 4.9% of Passage Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Passage Bio beats Ensysce Biosciences on 10 of the 14 factors compared between the two stocks.

How does Ensysce Biosciences compare to GT Biopharma?

Ensysce Biosciences (NASDAQ:ENSC) and GT Biopharma (NASDAQ:GTBP) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Ensysce Biosciences has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GT Biopharma has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. GT Biopharma's return on equity of 0.00% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
GT Biopharma	N/A	N/A	-102.03%

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Comparatively, 1.2% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Ensysce Biosciences' average media sentiment score of 0.00 equaled GT Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
GT Biopharma	Neutral

Ensysce Biosciences has higher revenue and earnings than GT Biopharma. Ensysce Biosciences is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	1.14	-$10.18M	-$3.35	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

Summary

GT Biopharma beats Ensysce Biosciences on 6 of the 10 factors compared between the two stocks.

Get Ensysce Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENSC vs. The Competition

Export

Metric	Ensysce Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.79M	$11.69B	$6.89B	$12.89B
Dividend Yield	N/A	2.73%	2.60%	10.01%
P/E Ratio	-0.11	791.57	280.82	25.46
Price / Sales	1.14	736.44	596.28	91.11
Price / Cash	N/A	71.54	72.11	49.40
Price / Book	0.60	10.85	12.99	6.09
Net Income	-$10.18M	$2.82B	$3.49B	$348.05M
7 Day Performance	48.73%	3.21%	3.43%	4.73%
1 Month Performance	32.39%	-2.07%	-2.63%	-2.14%
1 Year Performance	-83.14%	193.54%	73.71%	20.85%

Ensysce Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENSC Ensysce Biosciences	0.4146 of 5 stars	$0.38 -2.1%	N/A	-82.1%	$5.79M	$5.07M	N/A	10	Upcoming Earnings Gap Down
APLT Applied Therapeutics	1.5241 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30
TPST Tempest Therapeutics	1.0437 of 5 stars	$0.87 -6.8%	N/A	-88.1%	$14.93M	N/A	N/A	20	Upcoming Earnings
NAII Natural Alternatives International	0.4959 of 5 stars	$2.35 -0.8%	N/A	-37.5%	$14.87M	$129.86M	N/A	290
PASG Passage Bio	3.23 of 5 stars	$4.57 -1.1%	$13.25 +189.9%	-19.3%	$14.82M	N/A	N/A	130	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENSC) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ensysce Biosciences (ENSC) Competitors

ENSC vs. APLT, TPST, NAII, PASG, and GTBP

How does Ensysce Biosciences compare to Applied Therapeutics?

Summary

How does Ensysce Biosciences compare to Tempest Therapeutics?

Summary

How does Ensysce Biosciences compare to Natural Alternatives International?

Summary

How does Ensysce Biosciences compare to Passage Bio?

Summary

How does Ensysce Biosciences compare to GT Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENSC vs. The Competition

Ensysce Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ensysce Biosciences (ENSC) Competitors

ENSC vs. APLT, TPST, NAII, PASG, and GTBP

How does Ensysce Biosciences compare to Applied Therapeutics?

Do institutionals and insiders have more ownership in ENSC or APLT?

Does the media refer more to ENSC or APLT?

Do analysts prefer ENSC or APLT?

Which has more volatility and risk, ENSC or APLT?

Which has higher earnings & valuation, ENSC or APLT?

Is ENSC or APLT more profitable?

Summary

How does Ensysce Biosciences compare to Tempest Therapeutics?

Which has preferable earnings & valuation, TPST or ENSC?

Does the media favor TPST or ENSC?

Which has more volatility & risk, TPST or ENSC?

Do insiders and institutionals believe in TPST or ENSC?

Is TPST or ENSC more profitable?

Do analysts recommend TPST or ENSC?

Summary

How does Ensysce Biosciences compare to Natural Alternatives International?

Do analysts rate ENSC or NAII?

Is ENSC or NAII more profitable?

Do insiders & institutionals hold more shares of ENSC or NAII?

Which has better earnings and valuation, ENSC or NAII?

Which has more volatility & risk, ENSC or NAII?

Does the media refer more to ENSC or NAII?

Summary

How does Ensysce Biosciences compare to Passage Bio?

Which has more volatility and risk, ENSC or PASG?

Do analysts prefer ENSC or PASG?

Does the media refer more to ENSC or PASG?

Which has preferable valuation & earnings, ENSC or PASG?

Is ENSC or PASG more profitable?

Do insiders & institutionals have more ownership in ENSC or PASG?

Summary

How does Ensysce Biosciences compare to GT Biopharma?

Which has more risk & volatility, ENSC or GTBP?

Do analysts prefer ENSC or GTBP?

Is ENSC or GTBP more profitable?

Do insiders and institutionals have more ownership in ENSC or GTBP?

Does the media refer more to ENSC or GTBP?

Which has stronger earnings and valuation, ENSC or GTBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENSC vs. The Competition

Ensysce Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools